BioInvent International AB (OMXS: BINV) along with its collaborator Genentech, a member of a typical Roche Group, declared that each one affected individuals have finished selection in the GLACIER study, a phase IIa study with BI-204 in individuals with steady atherosclerotic vascular disorder. BioInvent hopes to publicly release top-line facts that came from the study in Q3 2012.Svein Mathisen, President and CEO of BioInvent, said that "Our Company and our partner, Genentech, are enthusiastically awaiting the outcomes from the GLACIER study. By making use of the latest invention in imaging technology all of us hope to show that BI-204 is delivering the treatment of atherosclerosis and intense coronary syndromes one step forward, addressing the disorder at its root, atherosclerotic plaque inflammation".
No comments:
Post a Comment